Pituitary Center, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA.
Trends Endocrinol Metab. 2010 Mar;21(3):123-33. doi: 10.1016/j.tem.2009.12.003. Epub 2010 Feb 9.
Somatotropin-release inhibitory factor (SRIF) is a major regulator of pituitary function, mostly inhibiting hormone secretion and to a lesser extent pituitary cell growth. Five SRIF receptor subtypes (SSTR1-5) are ubiquitously expressed G-protein coupled receptors. In the pituitary, SSTR1, 2, 3 and 5 are expressed, with SSTR2 and SSTR5 predominating. As new SRIF analogs have recently been introduced for treatment of pituitary disease, we evaluate the current knowledge of cell-specific pituitary SRIF receptor signaling and highlight areas of future research for comprehensive understanding of these mechanisms. Elucidating pituitary SRIF receptor signaling enables understanding of pituitary hormone secretion and cell growth, and also encourages future therapeutic development for pituitary disorders.
生长激素释放抑制因子(SRIF)是垂体功能的主要调节剂,主要抑制激素分泌,在较小程度上抑制垂体细胞生长。五种 SRIF 受体亚型(SSTR1-5)是广泛表达的 G 蛋白偶联受体。在垂体中,表达 SSTR1、2、3 和 5,其中 SSTR2 和 SSTR5 占主导地位。由于最近已经引入了新的 SRIF 类似物来治疗垂体疾病,因此我们评估了细胞特异性垂体 SRIF 受体信号传递的最新知识,并强调了未来研究的领域,以全面了解这些机制。阐明垂体 SRIF 受体信号传递可以帮助理解垂体激素分泌和细胞生长,也鼓励未来开发治疗垂体疾病的疗法。